Loading clinical trials...

A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC

NCT04175041•Massachusetts General Hospital

Summary

To determine the cognitive and neurophysiological dose-response relationships of anodal tDCS to the left DLPFC as a function of absolute current intensity, individualized E-field intensity, and stimulation duration.

Detailed Description

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Male and female outpatients 18-55 years of age
•2. A diagnosis of ADD/ADHD or meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
•3. Patient will be either off stimulant medications or, if undergoing treatment with stimulants, will be asked to discontinue two days prior to the experiment, under physician-guided protocol, and allowed to resume afterwards. Subjects may resume stimulant use between the two study visits so long as they discontinue use two days prior to the second study visit. If fatigue is problematic in subjects discontinuing medication, they will be allowed to continue with the study if they are able to follow the suggested taper plan (50% of the dose day one, 25% dose day 2, stop day of visit (day 3)).
•4. If on non-stimulant medications, dose must have been stable for at least 4 weeks.
•1\. Male and female outpatients 18-55 years of age

Exclusion Criteria

•1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.
•2. Active substance dependence (except for tobacco).
•3. Pregnant or nursing females.
•4. Inability to participate in testing procedures.
•1. Diagnosis of psychiatric of neurological disorder
•2. Ongoing treatment with any psychotropic medications.
•3. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.
•4. Active substance dependence (except for tobacco).
•5. Pregnant or nursing females.
•6. Inability to participate in testing procedures.

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

July 9, 2019

Primary Completion Date

May 1, 2026

Completion Date

May 1, 2026

Last Updated

December 12, 2025

Enrollment

104

ESTIMATED participants

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

Transcranial Direct Current Stimulation

DEVICE

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

NCT07189442

Attention Deficit Hyperactivity Disorder (ADHD)Autism Spectrum Disorder (ASD)

View study

RECRUITINGNA

Virtual Reality in Rehabilitation of Executive Functions in Children With Attention Deficit Hyperactivity Disorder.

NCT06123741

Attention Deficit Hyperactivity Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC

Inclusion Criteria

Exclusion Criteria

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

Virtual Reality in Rehabilitation of Executive Functions in Children With Attention Deficit Hyperactivity Disorder.

Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure

Effects of Probiotics on the Gut-brain Axis in Children

Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery

Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD